Previous 10 | Next 10 |
HOUSTON , March 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a new patent application has been...
Moleculin Biotech (NASDAQ: MBRX ): FY GAAP EPS of -$0.32 beats by $0.03 . More news on: Moleculin Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOUSTON , March 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced its financial results for the year ended Decemb...
VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company, announces, that its license partner Moleculin Biotech, Inc. (Nasdaq: MBRX)(ȁ...
Nano cap Moleculin Biotech ( MBRX +47.5% ) rallies on a healthy 15x surge in volume in reaction to its agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on the company's line-up of molecular inhibitors, including lead candidate WP1122, to asses...
March 17, 2020 Palm Beach, FL – March 17, 2020 – Chinese and western biotech companies have been gearing up to repurpose existing drugs, approved in the West for other viruses, as treatments for the coronavirus outbreak originating in Wuhan. Chinese authorities are testi...
HOUSTON , March 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that it has entered into an agreement with t...
HOUSTON , March 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that Dr. Hongbo Zhai , former Senior Faculty and...
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”), a clinical stage pharmaceutical company is pleased to provide an update on the clinical drug studies of Annamycin in Acute...
Moleculin Biotech ( MBRX +0.3% ) announces safety data from two Phase 1 studies, one in the U.S. and one in Europe , evaluating lead drug Annamycin in acute myeloid leukemia (AML) patients. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ... ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...